Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 15;615(7953):705–711. doi: 10.1038/s41586-023-05801-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a–c, CD8 antigen-specific responses to subcutaneous EL4-OVA tumour growth in mice given water (n = 8) or 0.72 mg ml⁻¹ Scrl (n = 7). a, Quantification of intratumoral CD8–MHC tetramer (K^b)–OVA-specific T cells. b, Representative flow cytometry plot of intratumoral cells re-stimulated with OVA peptide and analysed for IFNγ and CD44. c, Percentage OVA-specific T cells expressing IFNγ. d,e, The OT-I tumour-rejection model. Mice given water or 0.72 mg ml⁻¹ Scrl (n = 10 per condition). d, Schematic overview of the model. e, Volumes of EL4-OVA tumours. f,g,h, MHC-mismatched tumour model using Kras^G12D pancreatic ductal adenocarcinoma (PDAC) cells in recipient mice given water (n = 9) or 0.72 mg ml⁻¹ Scrl (n = 8). f, Schematic overview of the model. g, Tumour growth in FVB recipient mice. h, Tumour growth in Rag2^−/− recipient mice. i–k, C57BL/6J mice given water (n = 7) or 0.72 mg ml⁻¹ Scrl (n = 7) challenged with LmOVA. i, The percentage of splenic OVA-specific CD8⁺ T cells. j, Representative flow cytometry plot of splenocytes re-stimulated with OVA peptide and analysed for expression of CD44 and IFNγ. k, The percentage of splenic CD8⁺ T cells expressing IFNγ. l, Representative proliferation of Jurkat T cells in T cell media (Ctrl) or exposed to acute (Scrl), chronic (Scrl on/on) or transient (Scrl on/off) 0.5 mM Scrl. n = 3 per condition. representative of 3 independent experiments. m–p, T cell responses at day 7 after LmOVA infection. Mice given water (n = 7), 0.72 mg ml⁻¹ Scrl (n = 6) or 0.72 mg ml⁻¹ Scrl for 2 weeks followed by water for one week (n = 7, Scrl off). m, Schematic experimental overview. n, Percentage of splenic K^b–OVA-specific CD8⁺ T cells. o, The frequency of splenic Ki67⁺CD8⁺ T cells. p, The frequency of total IFNγ and granzyme B (GZMB) expression in splenic CD8⁺ T cells after re-stimulation with OVA peptide. Data are mean ± s.e.m. (a,c,e,g–i,k,l,n–p). Each dot represents a biological (a,c,e,g–i,k,n–p) or technical (l) replicate; data are representative of two (e,g,i,k) or three (l) independent experiments. Significance was tested using unpaired two-tailed Student’s t-test (a,c,i,k); Brown–Forsythe and Welch ANOVA test with Dunnett’s T3 comparison (n–p); two-way ANOVA (e,g,h). NS, not significant.

Source data